Q5. What is the present world scenario of intellectual property rights with respect to life materials? Although, India is second in the world to file patents, still only a few have been commercialized. Explain the reasons behind this less commercialization. (10M)
Kartavya Desk Staff
Introduction
Intellectual Property Rights (IPRs) in life materials, like genes and organisms, are pivotal for innovation but complex. Although India ranks second in patent filings, commercialization remains low, which limits its potential to leverage these innovations globally.
Present world scenario of IPRs with respect to life materials
• Biotechnology and Patents-Biotech advancements lead to patents on GMOs and stem cells, but nations vary in their patent policies.
E.g. CRISPR-Cas9 patented in the US, restricted in Europe.
• Ethical Concerns– Patenting life forms, such as genes and seeds, raises ethical issues related to monopolization.
E.g. BRCA1 gene patent by Myriad Genetics restricted patient access to testing.
• Developing Nations’ Stand-Countries like India resist patents on essential life materials to avoid corporate monopolies.
E.g. India denied Novartis’ Glivec patent for ensuring affordable drugs.
• TRIPS and Global Standards-The TRIPS Agreement mandates life material patenting, but nations have some flexibility for biodiversity protection.
E.g. TKDL protects Indian traditional knowledge from exploitation.
• Open Source Movements-Open access initiatives challenge restrictive patents, promoting free innovation in life sciences.
E.g. Open Source Seed Initiative opposes seed patenting for farmers’ benefit.
Reasons for Less Commercialization in India
• Weak Industry-Academia Linkage-Poor collaboration limits patents moving from labs to markets.
E.g. Many CSIR patents remain uncommercialized due to this gap.
• Funding Constraints-Innovators face limited venture capital for scaling patented technologies.
E.g. Biotech startups struggle to access commercialization funding.
• Regulatory Delays- India’s complex regulatory framework delays patent commercialization.
E.g. DCGI approvals for drugs take years, discouraging investors.
• Focus on Filing Over Commercialization-Academic institutions prioritize patent filings over market viability.
E.g. IITs often lack business models for commercial use of patents.
• Lack of Commercialization Infrastructure-India lacks robust incubators and accelerators for patent commercialization.
E.g. US incubators help startups scale, while India has fewer such systems.
• Global Competition- Indian patents face stiff competition from well-funded international corporations.
E.g. Indian pharma patents struggle to compete with Pfizer.
Solutions to improve commercialization
• Strengthen Industry-Academia Partnerships- Better collaboration can ensure practical application of research.
E.g. Technology Transfer Offices (TTOs) can connect academia with industry.
• Simplify Regulatory Processes- Streamlining approvals will reduce commercialization delays.
E.g. A single-window clearance for biotech patents can fast-track market entry.
• Provide Financial Support-Tax incentives and subsidies can encourage patent commercialization.
E.g. Expanding BIRAC to support patent scaling in startups.
• Enhance IP Awareness-Educating innovators on IP protection and commercialization strategies is essential.
E.g. Establishing IPR cells in universities to guide commercialization.
• Build Commercialization Infrastructure-Develop technology incubators and accelerators to support startups.
E.g. Biotech hubs in major Indian cities can help foster patent commercialization.
Conclusion
India has made significant strides in patent filings but lags in commercialization. Addressing regulatory, financial, and infrastructural challenges can transform India’s patents into commercially viable products, boosting its global position in life sciences and biotech.